洁特生物
(688026)
| 流通市值：31.88亿 | | | 总市值：31.88亿 |
| 流通股本：1.40亿 | | | 总股本：1.40亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 424,947,332.7 | 277,457,045.28 | 107,856,760.78 | 563,976,836.75 |
| 营业收入 | 424,947,332.7 | 277,457,045.28 | 107,856,760.78 | 563,976,836.75 |
| 二、营业总成本 | 391,934,810.5 | 257,287,868.6 | 113,800,338.52 | 485,139,596.82 |
| 营业成本 | 254,485,931.29 | 168,125,187.1 | 70,783,573.11 | 330,528,373.98 |
| 税金及附加 | 4,000,490.59 | 2,284,228.45 | 1,168,554.78 | 11,003,693.74 |
| 销售费用 | 30,217,614.47 | 18,675,516.56 | 9,711,276.48 | 37,719,271.77 |
| 管理费用 | 42,637,959.42 | 28,056,487.12 | 13,486,026.43 | 54,231,251.67 |
| 研发费用 | 27,403,357.33 | 15,979,344.58 | 7,077,500.06 | 29,122,819.08 |
| 财务费用 | 33,189,457.4 | 24,167,104.79 | 11,573,407.66 | 22,534,186.58 |
| 其中:利息费用 | 22,865,925.58 | 15,171,699.13 | 7,384,587.49 | 28,252,128.42 |
| 其中:利息收入 | 2,043,397.43 | 1,649,572.4 | 730,655.7 | 8,137,560.16 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | - | - | - | 238,219.18 |
| 加:投资收益 | 2,781,298.59 | 1,764,774.95 | 519,336.71 | 2,181,291.36 |
| 资产处置收益 | -397,782.74 | -434,950.88 | 11,504.42 | -801,080.79 |
| 资产减值损失(新) | -363,202.66 | 14,038 | - | -26,572,760.61 |
| 信用减值损失(新) | -1,162,929.95 | -369,099.04 | 1,334,193.27 | 920,033.54 |
| 其他收益 | 4,572,715.05 | 2,831,072.11 | 1,157,351.8 | 7,558,664.92 |
| 四、营业利润 | 38,442,620.49 | 23,975,011.82 | -2,921,191.54 | 62,361,607.53 |
| 加:营业外收入 | 485,109.66 | 51,132.06 | 34,866.91 | 165,982.73 |
| 减:营业外支出 | -363,619.95 | 13,212.8 | 12,947.8 | 1,593,534.01 |
| 五、利润总额 | 39,291,350.1 | 24,012,931.08 | -2,899,272.43 | 60,934,056.25 |
| 减:所得税费用 | 4,745,805.98 | 1,975,712.56 | 937,064.96 | 11,839,445.7 |
| 六、净利润 | 34,545,544.12 | 22,037,218.52 | -3,836,337.39 | 49,094,610.55 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 34,545,544.12 | 22,037,218.52 | -3,836,337.39 | 49,094,610.55 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 34,103,754.47 | 20,816,586.5 | -4,223,181.24 | 48,236,305.48 |
| 少数股东损益 | 441,789.65 | 1,220,632.02 | 386,843.85 | 858,305.07 |
| 扣除非经常损益后的净利润 | 28,645,770.62 | 18,112,757.76 | -5,396,440.31 | 36,460,806.57 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.24 | 0.15 | -0.03 | 0.35 |
| (二)稀释每股收益 | 0.24 | 0.15 | -0.03 | 0.35 |
| 八、其他综合收益 | -701,124.96 | -638,800.05 | -89,482.93 | 301,690.5 |
| 归属于母公司股东的其他综合收益 | -701,124.96 | -638,800.05 | -89,482.93 | 301,690.5 |
| 九、综合收益总额 | 33,844,419.16 | 21,398,418.47 | -3,925,820.32 | 49,396,301.05 |
| 归属于母公司股东的综合收益总额 | 33,402,629.51 | 20,177,786.45 | -4,312,664.17 | 48,537,995.98 |
| 归属于少数股东的综合收益总额 | 441,789.65 | 1,220,632.02 | 386,843.85 | 858,305.07 |
| 公告日期 | 2026-10-31 | 2026-08-31 | 2026-04-30 | 2026-04-30 |
| 审计意见(境内) | | | | 标准无保留意见 |